{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-047968","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.936289+00:00","generated_at":"2026-06-01T07:23:23.894328+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Relmada shareholders reject equity plan increase and say-on-pay at annual meeting","bullets":["Director John Glasspool received 7.7M for and 9.98M withheld; Paul Kelly had 11.8M for, 5.88M withheld.","Ratification of Marcum LLP as auditor approved: 19.98M for, 1.97M against.","Proposal to increase 2021 Equity Plan by 4.5M shares failed: 4.26M for, 13.41M against.","Advisory vote on executive compensation did not pass: 7.53M for, 10.12M against.","72.9% of outstanding shares (21.99M of 30.17M) were present at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-047968","json":"https://secwatch.observer/filing/0001213900-24-047968.json","markdown":"https://secwatch.observer/filing/0001213900-24-047968.md","text":"https://secwatch.observer/filing/0001213900-24-047968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047968/0001213900-24-047968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024047968/ea0207126-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:23:23.894328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}